| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
Breast Center, Departments of Medicine and Molecular and Cellular Biology, Baylor College of Medicine and Methodist Hospital, Houston, Texas
Requests for reprints: Xiaojiang Cui, Breast Center, Baylor College of Medicine, Houston, TX 77030. Phone: 713-798-1615; Fax: 713-798-1642; E-mail: cui{at}breastcenter.tmc.edu.
The epidermal growth factor (EGF) and insulin-like growth factor (IGF) signaling pathways are critically involved in cancer development and progression. However, how these two signals cross-talk with each other to regulate cancer cell growth is not clearly understood. In this study, we found that EGF remarkably induced expression of major IGF signaling components, insulin receptor substrate (IRS)-1 and IRS-2, an effect that could be blocked by EGF receptor (EGFR) tyrosine kinase inhibitors. Although both extracellular signal-regulated kinase and c-Jun NH2-terminal kinase (JNK) signaling pathways were involved in the EGF up-regulation of IRS-1, the IRS-2 induction by EGF was specifically mediated by JNK signaling. Consistent with this, EGF increased IRS-2 promoter activity, which was associated with recruitment of activator protein-1 (AP-1) transcription factors and was inhibited by blocking AP-1 activity. Moreover, EGF treatment enhanced IGF-I and integrin engagement-elicited tyrosine phosphorylation of IRS and their downstream signaling, such as binding to phosphatidylinositol 3'-kinase regulatory subunit p85. Finally, repressing the induction of IRS-2 levels abolished the EGF enhancement of cell motility, suggesting that increased IRS-2 is essential for the EGF regulation of breast cancer cell migration. Taken together, our results reveal a novel mechanism of cross-talk between the EGF and IGF signaling pathways, which could have implications in therapeutic applications of targeting EGFR in tumors. Because AP-1 activity is involved in breast cancer progression, our work may also suggest IRS-2 as a useful marker for aggressive breast cancer. (Cancer Res 2006; 66(10): 5304-13)
This article has been cited by other articles:
![]() |
M. A. Antonyak, B. Li, A. D. Regan, Q. Feng, S. S. Dusaban, and R. A. Cerione Tissue Transglutaminase Is an Essential Participant in the Epidermal Growth Factor-stimulated Signaling Pathway Leading to Cancer Cell Migration and Invasion J. Biol. Chem., July 3, 2009; 284(27): 17914 - 17925. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Kleinberg, T. L. Wood, P. A. Furth, and A. V. Lee Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions Endocr. Rev., February 1, 2009; 30(1): 51 - 74. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Pankratz, E. Y. Tan, Y. Fine, A. M. Mercurio, and L. M. Shaw Insulin Receptor Substrate-2 Regulates Aerobic Glycolysis in Mouse Mammary Tumor Cells via Glucose Transporter 1 J. Biol. Chem., January 23, 2009; 284(4): 2031 - 2037. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Wilsbacher, Q. Zhang, L. A. Tucker, R. D. Hubbard, G. S. Sheppard, N. Y. Bamaung, S. D. Fidanze, G. T. Wang, X. Hu, S. K. Davidsen, et al. Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation J. Biol. Chem., August 29, 2008; 283(35): 23721 - 23730. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yan, H. Erdem, R. Li, Y. Cai, G. Ayala, M. Ittmann, L.-y. Yu-Lee, S. Y. Tsai, and M.-J. Tsai Steroid Receptor Coactivator-3/AIB1 Promotes Cell Migration and Invasiveness through Focal Adhesion Turnover and Matrix Metalloproteinase Expression Cancer Res., July 1, 2008; 68(13): 5460 - 5468. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lahusen, M. Fereshteh, A. Oh, A. Wellstein, and A. T. Riegel Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1 Cancer Res., August 1, 2007; 67(15): 7256 - 7265. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Vona-Davis and D. P Rose Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression Endocr. Relat. Cancer, June 1, 2007; 14(2): 189 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Denley, J. M. Carroll, G. V. Brierley, L. Cosgrove, J. Wallace, B. Forbes, and C. T. Roberts Jr. Differential Activation of Insulin Receptor Substrates 1 and 2 by Insulin-Like Growth Factor-Activated Insulin Receptors Mol. Cell. Biol., May 15, 2007; 27(10): 3569 - 3577. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Ma, S. L. Gibson, M. A. Byrne, J. Zhang, M. F. White, and L. M. Shaw Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis Mol. Cell. Biol., December 15, 2006; 26(24): 9338 - 9351. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |